ImmunityBio (IBRX) announced the signing of a strategic memorandum of understanding with the Ministry of Investment of Saudi Arabia, King Faisal Specialist Hospital & Research Center and King Abdullah International Medical Research Center. This multi-party collaboration will introduce the FDA-approved Cancer BioShield platform to Saudi Arabia and the broader Middle East, paving the way for a new era of immune-restorative therapies for cancer patients. The announcement was made during the Saudi-U.S. Investment Forum 2025 in Riyadh, held alongside the state visit of U.S. President Donald Trump. The forum convened senior government officials, Fortune 500 executives, and global innovators to strengthen strategic ties and accelerate investments in sectors such as biotechnology, healthcare, clean energy, and AI.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IBRX:
- Piper upgrades ImmunityBio on Anktiva expansion opportunities
- ImmunityBio upgraded to Overweight from Neutral at Piper Sandler
- Short Report: Bears not fearing rebound in Rocket, Avis Budget shares
- ImmunityBio Sees Revenue Surge Amid Strong Sales Momentum
- ImmunityBio’s Promising Growth and Strategic Expansion Justify Buy Rating Despite Regulatory Setback